Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
- 24 February 2014
- journal article
- research article
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 2
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Cystic Fibrosis Transmembrane Conductance Regulator Intracellular Processing, Trafficking, and Opportunities for Mutation-Specific TreatmentChest, 2011
- Determination of the Minimal Clinically Important Difference Scores for the Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Scale in Two Populations of Patients With Cystic Fibrosis and Chronic Pseudomonas aeruginosa Airway InfectionChest, 2009
- Molecular targeting of CFTR as a therapeutic approach to cystic fibrosisTrends in Pharmacological Sciences, 2007
- Measuring inconsistency in meta-analysesBMJ, 2003
- The Phenotypic Consequences of CFTR MutationsAnnals of Human Genetics, 2003
- Cystic fibrosis: A worldwide analysis ofCFTR mutations?correlation with incidence data and application to screeningHuman Mutation, 2002
- In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR.Journal of Clinical Investigation, 1997
- Delta F508 in cystic fibrosis: willing but not ableArchives of Disease in Childhood, 1997
- Generation and characterization of a ΔF508 cystic fibrosis mouse modelNature Genetics, 1995
- Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNAScience, 1989